Figure 2 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network

Metabolic changes in MET-driven and non-MET-driven cancer cells and xenografts. A, Pathway enrichment analysis upon MET inhibition (N = 3, |log₂FC| > 0.5; adj. P value < 0.01) revealed alterations observed in 12 MET-expressing cell lines upon 24 hours of METi. B, Changes in the abundance of the three metabolite ions [5′-phosphoribosyl-N-formylglycinamide (FGAR), phosphoribosyl pyrophosphate (PRPP), and deoxythymidine diphosphate (dTDP)] that change most upon METi in MET-driven cell lines. Symbol sizes represent the adjusted P values from 1 (smallest) to 10⁻⁸ (largest) using a log scale. No significant changes in these ions occurred in the non-MET-driven cell lines H1648, H820, HCC827, and Y1248H. C, Left, Differences in metabolite ion (symbols) abundance in METi- and vehicle-treated tumor xenografts. Symbols corresponding to statistically significant differences (|log₂FC| > 0.5; P value < 0.01) are indicated in dark blue, and FGAR is marked in red. Right, Changes in the FGAR metabolite ion abundance in HCC827 and EBC-1 tumor xenografts upon METi.